Fondaparinux Sodium structure
|
Common Name | Fondaparinux Sodium | ||
|---|---|---|---|---|
| CAS Number | 114870-03-0 | Molecular Weight | 1738.16 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C31H53N3Na10O49S8 | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
Use of Fondaparinux SodiumFondaparinux sodium is an antithrombin-dependent factor Xa inhibitor. |
| Name | fondaparinux sodium |
|---|---|
| Synonym | More Synonyms |
| Description | Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor. |
|---|---|
| Related Catalog | |
| Target |
Factor Xa[1] |
| In Vitro | Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. For Fondaparinux, its IC50 values (anti-Xa IU/ml) are 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs)[2]. |
| In Vivo | Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation[1]. |
| References |
| Molecular Formula | C31H53N3Na10O49S8 |
|---|---|
| Molecular Weight | 1738.16 |
| PSA | 900.82000 |
| RIDADR | NONH for all modes of transport |
|---|
|
Structural Evidence for the Tetrameric Assembly of Chemokine CCL11 and the Glycosaminoglycan Arixtra™.
Biomolecules 3 , 905-22, (2014) Understanding chemokine interactions with glycosaminoglycans (GAG) is critical as these interactions have been linked to a number of inflammatory medical conditions, such as arthritis and asthma. To b... |
|
|
Bioengineered heparins and heparan sulfates.
Adv. Drug Deliv. Rev. 97 , 237-49, (2016) Heparin and heparan sulfates are closely related linear anionic polysaccharides, called glycosaminoglycans, which exhibit a number of important biological and pharmacological activities. These polysac... |
| α-D-glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), decasodium salt |
| Decasodium methyl 2-deoxy-6-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranosyl-(1->4)-β-D-glucopyranuronosyl-(1->4)-2-deoxy-3,6-di-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranosyl-(1->4)-2- O-sulfonato-α-L-idopyranuronosyl-(1->;4)-2-deoxy-6-O-sulfonato-2-(sulfonatoamino)-α-D-glucopyranoside |
| α-D-glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10) |
| Fondaparin sodium |
| Arixtra |
| Fondaparinux sodium |
| α-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4 )-O-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10) |
| Fondaparinux (sodium) |